Abstract:Abstract Background Donepezil is the most commonly prescribed medication for treating Alzheimer’s disease. However, the most commonly used once daily oral formulation or recently developed once or twice weekly patch formulations have side effects such as nausea, vomiting and weight loss or skin irritation, and the patient’s compliance with these medications is very low. One month release injectable of donepezil microspheres can be a good alternative to increase patient compliance and reduce these side effects. The biggest obstacle in the development of one month donepezil microspheres is that patients tend to feel pain at the injection site due to the large volume of dosage. We have developed novel donepezil microspheres with high drug contents which can improve patient compliance and medication convenience by lowering dosage volume at the injection site. Method Mono‐dispersed and spherical shaped donepezil microspheres with different drug contents were manufactured by membrane emulsification method. The morphology of the microspheres was observed by electron microscope, and the particle size distribution was measured by laser diffraction analysis. The donepezil contents in the microspheres were analyzed using HPLC. Pharmacokinetic studies were performed after a single injection in male SD rats. The concentration of donepezil in the plasma samples was determined by LC‐MS/MS. Result Donepezil microspheres with three different drug contents (27%, 45% and 60%) were prepared successfully with high drug encapsulation efficiency. All the donepezil microspheres regardless of high drug content have a spherical shape and smooth surface with a narrow side distribution. Despite the high content of donepezil, the initial release was well controlled to less than 5% during the first 24 hours after injection. In rat PK studies of donepezil microspheres after a single injection, plasma donepezil concentration of all three formulations was kept within the therapeutic range for more than one month. Conclusion We have developed novel donepezil microspheres with high drug contents and without initial burst release. These high donepezil‐loaded microspheres can improve patient compliance and medication convenience by lowering dosage volume at the injection site. Currently, this novel donepezil formulation is planned for commercialization after clinical trials.

Novel ionically crosslinked acrylamide-grafted poly(vinyl alcohol)/sodium alginate/sodium carboxymethyl cellulose pH-sensitive microspheres for delivery of Alzheimer's drug donepezil hydrochloride: Preparation and optimization of release conditions

Construction and Characterization of Thermosensitive Hydrogel Loaded with Donepezil Nanosuspension and its Application for Transnasal Delivery

Effects of Formulation Factors on Encapsulation Efficiency and Release Behaviour in Vitro of Huperzine A-Plga Microspheres

Preparation and Evaluation of Orally Disintegrating Film Containing Donepezil for Alzheimer Disease

Preparation, characterization, and in vivo pharmacokinetics of thermosensitive in situ nasal gel of donepezil hydrochloride

In Vitro and in Vivo Evaluation of Donepezil-Sustained Release Microparticles for the Treatment of Alzheimer'S Disease

Preparation and Drug Release Study of Novel Nanopharmaceuticals with Polysorbate 80 Surface Adsorption

Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice.

In Vitro Neuroprotective Effect Evaluation of Donepezil‐Loaded PLGA Nanoparticles‐Embedded PVA/PEG Nanofibers on SH‐SY5Y Cells and AP‐APP Plasmid Related Alzheimer Cell Line Model

Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer’s Disease

Mefenamic Acid Loaded and TPGS Stabilized Mucoadhesive Nanoemulsion for the Treatment of Alzheimer's Disease: Development, Optimization, and Brain-Targeted Delivery via Olfactory Pathway

Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study

Chitosan-Based Thermogelling System for Nose-to-Brain Donepezil Delivery: Optimising Formulation Properties and Nasal Deposition Profile

Novel High‐Donepezil Loaded One‐Month Release Microspheres for Alzheimer’s Disease Treatment

Fabrication and in vitro drug release study of microsphere drug delivery systems based on amphiphilic poly-alpha,beta-[N-(2-hydroxyethyl)-L-aspartamide]-g-poly(L-lactide) graft copolymers.

Fabrication and in vitro drug release study of microsphere drug delivery systems based on amphiphilic poly-α,β-[N-(2-hydroxyethyl)-l-aspartamide]-g-poly(l-lactide) graft copolymers

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer's disease

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate)-based microspheres as a sustained platform for Huperzine A delivery for alzheimer's disease therapy

Hierarchical Adhesive Hydrogel Microparticles with Galantamine Hydrobromide Encapsulation for Alzheimer’s Disease

Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease

Tailoring functional spray-dried powder platform for efficient donepezil nose-to-brain delivery